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SUMMARY
Poor penetration of drugs into tumors is a major obstacle in tumor treatment. We describe a strategy for
peptide-mediated delivery of compounds deep into the tumor parenchyma that uses a tumor-homing
peptide, iRGD (CRGDK/RGPD/EC). Intravenously injected compounds coupled to iRGD bound to tumor
vessels and spread into the extravascular tumor parenchyma, whereas conventional RGD peptides only
delivered the cargo to the blood vessels. iRGD homes to tumors through a three-step process: the RGDmotif
mediates binding to av integrins on tumor endothelium and a proteolytic cleavage then exposes a binding
motif for neuropilin-1, which mediates penetration into tissue and cells. Conjugation to iRGD significantly
improved the sensitivity of tumor-imaging agents and enhanced the activity of an antitumor drug.INTRODUCTION
The vasculature in different tissues expresses distinct biochem-
ical signatures, the ‘‘vascular zip codes’’ (Ruoslahti, 2002; Ruo-
slahti and Rajotte, 2000). Vascular zip codes can serve as targets
for docking-based (synaphic) delivery of diagnostics and thera-
peutics. av integrins are highly expressed in tumor vasculature,
where they can be accessed with peptides containing the RGD
integrin recognition motif (Eliceiri and Cheresh, 2001; Piersch-
bacher and Ruoslahti, 1984; Ruoslahti, 2002, 2003). RGD-based
synaphic targeting has been successfully used to deliver drugs,
biologicals (Arap et al., 1998; Curnis et al., 2004), imaging agents
(Sipkins et al., 1998), viruses (Pasqualini et al., 1997; Wickham,
2000), and nanoparticles (Murphy et al., 2008) to tumor vascula-
ture. However, crossing the vascular wall and penetrating into
the tumor parenchyma against the elevated interstitial pressure
in tumors remains a major challenge in tumor therapy (Heldin
et al., 2004; Jain, 1990).510 Cancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc.We have recently identified a consensus R/KXXR/K motif as
a mediator of cell and tissue penetration (Teesalu et al., 2009).
The receptor for the R/KXXR/K motif was shown to be neuropi-
lin-1. This motif is not active unless it occupies a C-terminal posi-
tion in the peptide; we refer to this position effect as the C-end
Rule (CendR).
The interaction between the CendR motif and neuropilin-1
appears to be a key determinant for penetration of biological
barriers. For example, vascular endothelial growth factor-165
and certain semaphorins bind to neuropilin-1 through C-terminal
CendR motifs and thereby increase vascular permeability (Ace-
vedo et al., 2008; Jia et al., 2006; Soker et al., 1998; Teesalu
et al., 2009). In addition, many viruses possess CendR motifs
within their capsid proteins and often require proteolytic
cleavage to expose the CendR motif to be infective, a process
that requires penetration of biological barriers (Steinhauer,
1999; Teesalu et al., 2009). One such virus, HTLV-1, has been
shown to use its CendR motif (KPXR) to bind to and internalizeSIGNIFICANCE
Targeted delivery of compounds to tumor vessels and tumor cells can enhance tumor detection and therapy. Docking-
based (synaphic) targeting strategies use peptides, antibodies, and other molecules that bind to tumor vessels and tumor
cells to deliver more drug to tumors than to normal tissues. A major obstacle to applying this principle has been the limited
transport of the targeted payload into tumor parenchyma. The iRGD peptide we describe here overcomes this limitation and
establishes a capability for tissue-penetrating drug delivery.
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iRGDFigure 1. Identification of iRGD Peptide
(A) A representative example of the enrichment
obtained in phage library screens on prostate
cancer bone metastases. Three screens with
similar results were performed.
(B) RGD peptides selected in the screens. Approx-
imately 50 individual clones were randomly picked
for sequencing from phage pools recovered in the
final round of ex vivo phage display. Clones that
gave unsuccessful sequencing results were
omitted during the analysis. The proportion of
each RGD peptide is shown.
(C) Binding and internalization to PPC1 human
prostate cancer cells of phage expressing the
CRGDKGPDC peptide. PPC1 cells were incu-
bated with phage displaying CRGDKGPDC or
a polyglycine control peptide CG7C for 1 hr at
4C or 37C. To assess internalization, phage
bound at the cell surface was removed by washing
the cells with an acid buffer. Note that the internal-
ization of CRGDKGPDC phage occurs at 37C
but not at 4C. Statistical analysis was performed
with Student’s t test. n = 3; error bars, SEM;
***p < 0.001.into immune cells in a neuropilin-1-dependent fashion to infect
the cells (Lambert et al., 2009).
We hypothesized that the tissue-penetrating properties of the
CendR system could be used to deliver drugs and nanoparticles
into tumor parenchyma, beyond the vascular barrier. Here we
report results obtained with a peptide that combines tumor-
homing and CendR-dependent tissue-penetrating properties.
We also evaluate the potential of the technology for clinical appli-
cations by performing magnetic resonance imaging (MRI) and
tumor treatment studies.
RESULTS
Identification of iRGD
We used a cyclic CX7C (C, cysteine; X, any amino acid) peptide
library displayed on T7 phage (diversity approximately 109; Hoff-
man et al., 2003) to identify peptides that recognize tumor blood
vessels in experimental metastasis mouse models of human
prostate cancer (see Figure S1 available online). Three rounds
of ex vivo phage display selection with cell suspensions from
bone tumors were followed by one in vivo selection for homing
to the bone tumors (Hoffman et al., 2003). The resulting phage
pools bound to tumor-derived cell suspensions 200–400 times
more than the original library, and the binding to the tumor cell
suspensions was five times higher than to cell suspensions
from normal bone (Figure 1A). Individual phage clones were
randomly picked from the phage pools and sequenced. Phage
that contained the RGD motif (Pierschbacher and Ruoslahti,
1984; Ruoslahti, 2003) within three related sequences,
CRGDKGPDC, CRGDRGPDC, and CRGDKGPEC, dominated
in the selected pools (Figure 1B). CRGDKGPDC, which was
most frequent, bound to cultured PPC1 human prostate cancer
cells at 4C, appeared to internalize into them at 37C
(Figure 1C), and was named ‘‘iRGD’’ (internalizing RGD).CHoming of iRGD to Tumors
We synthesized a fluorescein-labeled iRGD (FAM-iRGD) and
intravenously injected the peptide into tumor-bearing mice.
FAM-iRGD accumulated in tumor tissue in every model we
tested. These include orthotopic xenografts of prostate, pancre-
atic ductal, and breast cancer; bone and brain xenografts of
prostate carcinoma; and genetically engineered models of de
novo pancreatic neuroendocrine (islet), pancreatic ductal, and
cervical cancer (summarized in Table S1). The tumors, but not
normal tissues, were strongly fluorescent under UV light
(Figure 2A and Figure S2). Confocal microscopy revealed accu-
mulation of FAM-iRGD peptide in and around tumor vessels and
in tumor parenchyma (Figure 2B), but not in normal tissues
(Figure S3). Remarkably, iRGD phage (diameter about 65 nm;
Sokoloff et al., 2000) and a synthetic iRGD-coated nanoparticle,
self-assembling micelles (diameter 15–25 nm; Arleth et al., 2005;
Karmali et al., 2009), also reached extravascular tumor paren-
chyma (Figures 2B). Two conventional RGD peptides and their
corresponding peptide-displaying phage, CRGDC and RGD-
4C, which both have strong affinities for av integrins (Koivunen
et al., 1993, 1995), also homed to tumors, but accumulated
only in and around tumor blood vessels and did not disperse
throughout the interstitium like iRGD (Figure 2B). Quantification
of the area of peptide homing further demonstrated that iRGD
homes to and spreads within the tumor tissue far more efficiently
than CRGDC (Figure 2C). The difference in the distribution of
payloads linked to iRGD and other RGD peptides was even
more pronounced when a genetically engineered model of de
novo pancreatic ductal adenocarcinoma (PDAC; Hezel et al.,
2006) with an extensive amount of interstitium was used as the
target (Figure S4). Whole-body imaging of PDAC mice injected
with FAM-iRGD micelles labeled with the near-infrared dye
Cy7 produced a strong and specific signal in the tumors, illus-
trating the potential of iRGD for tumor targeting (Figure S5).ancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc. 511
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iRGDFigure 2. In Vivo Tumor Homing of iRGD Peptide
(A) Approximately 200 mg of FAM-iRGD or control peptide in PBS was intrave-
nously injected into KrasG12D, p48-Cre, Ink4a+/ mice bearing de novo PDAC.
The peptides were allowed to circulate for 2 hr and organs were collected and
viewed under UV light. Arrowheads point to the tumors. Dotted lines show
where the organs were placed. Representative images from four experiments
are shown.
(B) Confocal images of orthotopic 22Rv1 human prostate cancer xenografts
from mice injected with the indicated peptides, phage, and micelles. iRGD
was compared to a similar integrin-binding but nonpenetrating peptide,
CRDGC. The circulation time was 2 hr for the free peptides, 15 min for the
phage, and 3 hr for the micelles. Red, CD31; green, peptides, phage, or
micelles; blue, nuclei. Arrows point to CRGDC compounds in or just outside
the vessel walls, illustrating its homing to the tumor vasculature. Representa-
tive fields from multiple sections of five tumors are shown. Scale bars, 50 mm.
(C) Quantification of tumor homing area of iRGD and CRGDC peptides. Cryo-
sections of 22Rv1 orthotopic tumors from mice injected with FAM-iRGD or
FAM-CRGDC peptide were immunohistochemically stained with an anti-
FITC antibody. The samples were subjected to image analysis with Scanscope
CM-1 scanner for quantification of the FAM-positive areas. Statistical analysis
was performed with Student’s t test. n = 3; error bars, SEM; ***p < 0.001.512 Cancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc.Integrin-Dependent Binding of iRGD to Tumor Cells
The in vivo homing of iRGD to tumors is dependent on the
RGD motif. Control peptides including a nonintegrin binding
variant (Pierschbacher and Ruoslahti, 1984; Ruoslahti, 2003),
CRGEKGPDC (iRGE), produced minimal tumor fluorescence
(Figure 3A). Coinjecting an excess of unlabeled iRGD peptide
Figure 3. iRGD Binds to av Integrins
(A) Quantification of the in vivo distribution of iRGD and control peptides. FAM-
iRGD; a non-integrin-binding iRGD mutant, FAM-CRG(E)KGPDC (FAM-iRGE);
and a FAM-labeled cyclic polyglycine control peptide, FAM-CG7C, were
injected into PDAC mice as described in Figure 2A. Fluorescence in each
tissue was quantified with Image J.
(B) Inhibition of the tumor homing of FAM-iRGD with nonlabeled iRGD. A 10-
fold excess of unlabeled iRGD peptide or iRGE peptide was injected 30 min
before the injection of FAM-iRGD in PDAC mice. Fluorescence was quantified
as above. FAM-iRGD homing without injection of unlabeled peptide was
considered as 100%.
(C) Dose-dependent inhibition of iRGD phage binding to PPC1 prostate cancer
cells by synthetic iRGD peptide and iRGE. iRGD phage binding without inhib-
itors was considered as 100%.
(D) Inhibition of iRGD phage binding to av integrin expressing M21 cells by anti-
bodies against integrins or control mouse IgG (left panel). Lack of iRGD phage
binding to M21 cells selected for low level of av integrin expression (M21L;
right panel). Statistical analyses were performed with Student’s t test in (A)
and (B) and with ANOVA in (C) and (D). n = 3; error bars, SEM; *p < 0.05;
**p < 0.01; ***p < 0.001.
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iRGDreduced the accumulation of FAM-iRGD in tumors, whereas
iRGE peptide did not have such an effect (Figure 3B). The
in vitro binding of iRGD to cancer cells also required the RGD
motif because the binding of iRGD phage to PPC1 cells at 4C
was inhibited dose dependently by free iRGD peptide, but not
by iRGE (Figure 3C).
The RGD-directed integrins avb3, avb5, and a5b1 are upregu-
lated in angiogenic endothelial cells and certain tumor cells
(Eliceiri and Cheresh, 2001; Ruoslahti, 2002). PPC1 cells express
avb5 and a5b1, but not avb3 (Figure S6A). An anti-avb5 antibody
almost completely inhibited iRGD phage binding to PPC1 cells,
whereas inhibitory antibodies against a5b1 and other integrins
had no effect (Figure S6B). M21 human melanoma cells (Cheresh
and Spiro, 1987; Figure S7) expressing both avb3 and avb5
integrins bound iRGD phage, whereas variants lacking expres-
sion of these integrins did not, confirming the av integrin depen-
dency of iRGD binding (Figure 3D). The binding of the iRGD
phage was reduced by both anti-avb3 or anti-avb5 (Figure 3D),
indicating that iRGD recognizes both of these integrins.
The binding affinity of synthetic iRGD peptide to purified avb3
integrin was Kd = 17.8 ± 8.6 nM and Kd = 61.7 ± 13.3 nM to avb5
integrin (Table S2). The affinities of two previously identified
cyclic RGD peptides, RGD-4C and CRGDC (Koivunen et al.,
1993, 1995), for avb3 and avb5 were also in the same range,
as shown by measuring the ability of each peptide to block
iRGD binding (Table S2). Thus, differences in integrin-binding
specificity or affinity do not explain the distinct ability of iRGD
from the other two RGD peptides to penetrate tumor cells and
tissue. Rather, the evidence implicates a second motif in iRGD,
dubbed the CendR motif, in this capability.
iRGD as a CendR Peptide
iRGD contains a cryptic CendR motif, RGDK/R, and possesses
CendR-like tissue and cell-penetrating activities (Teesalu et al.,
2009). However, the CendR motif in iRGD is not C-terminal,
which is a prerequisite for CendR activity (Teesalu et al., 2009).
Therefore, we hypothesized that iRGD, having been recruited
to cell surfaces through the RGD-integrin interactions, is proteo-
lytically processed and that the processing generates a C-ter-
minal RGDK/R sequence capable of binding to neuropilin-1
(schematized in Figure 4).
To investigate this proteolysis hypothesis, we first examined
whether iRGD binds to PPC1 cells in a CendR-dependent
manner after being treated by a protease to expose a C-terminal
arginine or lysine; PPC1 cells have substantial levels of neuropi-
lin-1 expression (Teesalu et al., 2009). Because the protease(s)
that we postulate to cleave iRGD is unknown, we chose to use
trypsin for this purpose, as its specificity predicts that it would
produce a derivative iRGD peptide with the requisite C-terminal
arginine or lysine. As shown in Figure 5A, trypsin treatment of
iRGD phage enhanced the binding of iRGD phage to PPC1 cells
to a level comparable to a prototypic CendR peptide, RPARPAR
(Teesalu et al., 2009). Trypsin had no effect on phage expressing
CRGDC (Figure 5A) or RGD-4C (data not shown). The binding at
4C of the trypsin-treated iRGD phage was blocked by UV-
treated noninfectious phage expressing RPARPAR, but not by
phage displaying a peptide in which the CendR motif was disrup-
ted by addition of an alanine residue to the C terminus (RPAR-
PARA; Teesalu et al., 2009). The binding of intact iRGD phageCwas not affected by RPARPAR (data not shown), supporting
our hypothesis that iRGD does not exhibit CendR features unless
its CendR motif is activated by exposure at the C terminus.
To determine whether the CendR motif in iRGD is indeed
activated by cellular proteases, we incubated FAM-iRGD that
carries the fluorophore at its N terminus with PPC1 prostate
cancer cells and isolated intracellular products by affinity chro-
matography on anti-FITC (FAM) antibodies. To prevent cyto-
plasmic proteolysis, while allowing proteolysis at the cell sur-
face, the incubation was done in the presence of a proteasome
inhibitor. We detected no intracellular full-length FAM-iRGD,
but recovered the FAM-CRGDK fragment (Figure S8). When
iRGD with FAM on its C terminus was used, no intracellular
iRGD fragment was recovered (data not shown). These results
show that CRGDK, the N-terminal half of iRGD with a C-terminal
CendR motif, is the cell-penetrating fragment of iRGD, as postu-
lated in Figure 4.
Prompted by the results indicating that proteolytically released
CRGDK is the active cell-penetrating component of iRGD, we
engineered phage expressing CRGDK and found that it bound
to and penetrated into PPC1 cells. The binding of the CRGDK
phage was inhibited by CRGDK peptide, indicating a specific
binding (Figure 5B). The binding process was also inhibited by
the RPARPAR peptide, which has a C-terminal arginine, but
not by RPARPARA (Figure 5B). Antibodies against various integ-
rins, including av integrins, had no effect on the CRGDK binding,
indicating that the binding is CendR dependent and does not
Figure 4. Multistep Binding and Penetration Mechanism of iRGD
The iRGD peptide accumulates at the surface of av integrin-expressing endo-
thelial and other cells in tumors. The RGD motif mediates the integrin binding.
The peptide is cleaved by a cell surface-associated protease(s) to expose the
cryptic CendR element, RXXK/R, at the C terminus (red dotted line). The
CendR element then mediates binding to neuropilin-1, with resulting penetra-
tion of cells and tissues. The peptide can penetrate into tumor cells and tissues
with a cargo, such as a simple chemical or a nanoparticle, provided that the
cargo is attached to the N terminus of the iRGD peptide because the disulfide
bond apparently breaks before the peptide is internalized (black line).ancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc. 513
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iRGDinvolve integrins (data not shown). Moreover, an antibody
against neuropilin-1, the receptor for CendR peptides (Teesalu
et al., 2009), reduced the binding (Figure 5C). CRGDK phage
did not substantially bind to or penetrate into M21 cells, which
express only minimal amounts of neuropilin-1 (Figure S9).
However, forced expression of neuropilin-1 in these cells (Tee-
salu et al., 2009) increased the binding (Figure 5D) and penetra-
tion (data not shown) approximately 3.5 fold. Affinity measure-
ments revealed that the CRGDK peptide binds to neuropilin-1
with a Kd (1.4 ± 0.6 mM; Table S2) similar to that of RPARPAR
(Kd = 1.7 ± 0.2 mM; Teesalu et al., 2009). These results indicate
that CRGDK binds to cells and penetrates into them using the
CendR pathway.
In keeping with the possibility that the RGDK CendR element is
the cell-penetrating sequence in iRGD, both CRGDK and RPAR-
PAR UV-treated phage inhibited iRGD phage penetration into
PPC1 cells at 37C (Figure 5E). Anti-neuropilin-1 also inhibited
Figure 5. CendR Motif in iRGD Penetration
of Tumor Cells
(A) The penetration of trypsin-treated iRGD phage
within PPC1 cells pretreated or not with noninfec-
tious RPARPAR or RPARPAR(A) phage.
(B) Inhibition of CRGDK phage binding to PPC1 by
synthetic CRGDK, RPARPAR, and RPARPAR(A)
peptides. CRGDK phage binding without inhibi-
tors was considered as 100%.
(C) CRGDK phage binding to PPC1 cells treated
with anti-neuropilin-1 blocking antibodies (anti-
NRP-1) or control goat IgG.
(D) CRGDK phage binding to M21 cells trans-
fected with neuropilin-1 cDNA to induce forced
expression of neuropilin-1 (NRP-1), vector alone,
or without transfection.
(E) Inhibition of iRGD and iRGE phage penetration
into PPC1 by noninfectious phage displaying the
CendR peptides RPARPAR and CRGDK.
(F) Dose-dependent inhibition of iRGD phage
penetration of PPC1 cells by anti-neuropilin-1 anti-
bodies (anti-NRP-1) to block neuropilin-1 function.
Statistical analyses were performed with ANOVA
in (A), (B), and (E) and Student’s t test in (C),
(D), and (F). n = 3; error bars, SEM; *p < 0.05;
**p < 0.01; ***p < 0.001.
the penetration of iRGD phage (Figure 5F),
but had little effect on binding of iRGD
phage to PPC1 cells at 4C (data not
shown). We further tested the relative
roles of the RGD and RXXK motifs in
iRGD by using the iRGE phage, which
does not bind to integrins due to the dis-
rupted RGD motif (Pierschbacher and
Ruoslahti, 1984; Ruoslahti, 2003), but still
contains a CendR motif, RXXK. The iRGE
phage did penetrate PPC1 cells at 37C,
and both RPARPAR and CRGDK in-
hibited the penetration (Figure 5E), impli-
cating the CendR pathway. The penetra-
tion was less effective than that of iRGD,
presumably because iRGE lacks integrin
binding that would concentrate the phage at the cell surface.
These results indicate that iRGD penetrates cells through the
CendR pathway using the RXXK sequence and that the penetra-
tion is likely facilitated by initial binding to integrins through RGD.
Confocal microscopy showed that iRGD phage and neuropilin-
1 colocalized in cultured cells (Figure S10), supporting the involve-
ment of the neuropilin-1-dependent CendR pathway in the tumor
cell penetration by iRGD. Phage displaying an iRGD variant that
lacks the CendR motif (CRGDGGPDC) or the two other conven-
tional RGD peptides, CRGDC and RGD-4C, did not colocalize
with neuropilin-1, nor did they penetrate the cells efficiently.
Neuropilin-1-Dependent Penetration
of iRGD within Tumor Tissue
We next investigated the neuropilin-1 dependence of in vivo
tissue penetration by iRGD into PDAC. Preinjection of tumor-
bearing mice with a function-blocking anti-neuropilin-1 antibody514 Cancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc.
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iRGDinhibited the penetration of iRGD phage in tumor tissue. The
phage were trapped in the tumor blood vessels or stayed in close
association with the vessels (Figure 6A, right panel). Preinjection
of control IgG did not affect the spreading of iRGD (Figure 6A, left
panel). Phage expressing the iRGD variant that lacks the CendR
motif but retains RGD (CRGDGGPDC) targeted tumor blood
vessels, but did not spread into tumor tissue (data not shown).
Studies on the time dependence of iRGD homing and penetra-
tion further supported the importance of av integrin and neuropi-
lin-1 expression in this process. FAM-iRGD peptide injected
intravenously into mice bearing PDAC tumors initially colocalized
with tumor blood vessels, which were positive for both av integ-
rins and neuropilin-1 (Figure 6B, top panels, arrows). The peptide
subsequently extravasated, presumably because it induces
increased permeability in tumor vessels (Teesalu et al., 2009),
and gradually appeared within tumor cells in ductal structures
(Figure 6B, middle panels). Most of the tumor cells were positive
for av integrins (Figure 6B, left panels). Importantly, tumor cells
strongly positive for neuropilin-1 were particularly effective at
accumulating and retaining FAM-iRGD (Figure 6B, right panels).
Similar results were obtained in an orthotopic prostate cancer
xenograft model; the iRGD peptide also homed to areas that
overexpress both av integrins and neuropilin-1 in these tumors.
The human 22Rv1 prostate cancer cells used in the model
express av integrins and neuropilin-1 on the cell surface (Figures
S11A and S11B).
iRGD in Tumor Imaging and Treatment
To investigate the potential of iRGD for clinical applications, we
performed MRI and therapeutic targeting experiments. For
MRI, mice bearing 22Rv1 orthotopic xenografts were injected
intravenously with iRGD peptide-linked superparamagnetic
iron oxide nanoworms (about 80 nm long and 30 nm thick;
Park et al., 2009; Simberg et al., 2007). Iron oxide nanoparticles
are evidenced as hypointensities in T2-weighted magnetic reso-
nance images (McAteer et al., 2007). In addition to hypointense
vascular signals, the iRGD nanoworms gave low intensity regions
that spread throughout the tumor, while CRGDC nanoworms
only decreased the intensity of the tumor vasculature (Figure 7,
T2-weighted magnetic resonance images). Untargeted nano-
worms produced no detectable signal under identical imaging
conditions. Confocal microscopy of the tumors confirmed the
enhanced tissue penetration of the iRGD nanoworms (Figure 7,
rightmost panels). Both the MRI results and optical imaging (Fig-
ure S5) indicate that iRGD is capable of delivering diagnostics to
tumors and that tumors are more efficiently visualized with this
peptide than with conventional RGD peptides.
The ability of iRGD to deliver anticancer drugs was investigated
by treating mice bearing orthotopic 22Rv1 tumors with iRGD-
coated abraxane, a 130 nm nanoparticle consisting of albumin-
embedded paclitaxel (Haley and Frenkel, 2008; Karmali et al.,
2009). In vitro, iRGD-abraxane inhibited the proliferation of
22Rv1 cells more efficiently than abraxane conjugated with
a cyclic RGD peptide without a CendR motif (CRGDC; Koivunen
et al., 1993) or abraxane alone (Figure S12A). Intravenously in-
jected iRGD-abraxane spread more within tumor tissue than
the other abraxane formulations (Figures S12B). Quantification
of the drug showed that 8-fold more abraxane accumulated in
the tumors from injections of iRGD-abraxane than of nontargetedCFigure 6. Penetration of iRGD within Tumor Tissue Involves Neuro-
pilin-1
(A) Neuropilin-1-dependent spreading of iRGD phage within tumor tissue.
Confocal images of PDAC tumors from transgenic mice preinjected with
a function-blocking anti-neuropilin-1 antibody (anti-NRP-1) or an IgG-control,
followed by injection with the iRGD phage. Green, phage; red, CD31; blue,
DAPI. Arrows and asterisks represent blood vessels and tumor ducts, respec-
tively. Representative images from three independent sets of studies are
shown. Scale bars, 50 mm.
(B) Time-dependent homing of FAM-iRGD peptide (green) in relation to the
expression of av integrins (red, left panels) and neuropilin-1 (red, right panels)
in PDACs. The blood vessels targeted by FAM-iRGD were positive for both av
integrins and neuropilin-1 (arrows). The inset shows CD31 staining (magenta)
of a blood vessel targeted by FAM-iRGD. Nearly all tumor ducts examined
were positive for av integrins. Tumor cells (arrowheads) and tumor ducts
(asterisks) also strongly positive for neuropilin-1 were particularly effective in
internalizing and retaining FAM-iRGD. Representative images from three inde-
pendently studied tumors at each time point are shown. Scale bars, 50 mm.ancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc. 515
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iRGDFigure 7. Tumor Imaging with iRGD-Coated
Iron Oxide Nanoworms
T2-weighted magnetic resonance images of mice
bearing orthotopic 22Rv1 human prostate tumors.
The mice were injected intravenously with iron
oxide nanoworms coated with iRGD, CRGDC, or
no peptide (5 mg/kg of iron). Shown are axial
images through the tumors acquired by repeated
imaging before the nanoworm injection (Preinjec-
tion) and 3 hr or 7 hr after the injection. The orien-
tation of the tumors is slightly different between
the time points because the mice were anesthe-
tized for each scan and reintroduced in the MRI
instrument. Gadolinium (Gd) was used as a refer-
ence for T1 and Feridex (Fe) for T2 imaging agents.
Note the wide hypointensity areas indicating the
spreading of iRGD nanoworms in the tumor inter-
stitium. CRGDC nanoworms only decreased the
intensity of tumor vessels, and the untargeted
nanoworms gave no signal in the tumor. Arrows
point to the vasculature. T, tumor; B, urinary
bladder. The rightmost panels represent the nano-
worm distribution in tumor tissue examined by
confocal microscopy. Green, nanoworms; red,
CD31; blue, DAPI. Scale bars, 100 mm. The images
are representative of multiple tumor mice; iRGD
nanoworms, n = 5; CRGDC nanoworms, n = 3;
untargeted nanoworms, n = 3.abraxane (Figure 8A). CRGDC-abraxane concentration was only
about 2-fold higher than that of nontargeted abraxane in the
tumors. In line with these results, iRGD-abraxane treatment re-
sulted in significant inhibition of tumor growth at a dose at which
untargeted abraxane showed no significant effect (Figure 8B); the
slight reduction in tumor growth in the CRGDC group was not
statistically significant. Treatment with the iRGD peptide alone
at a dose equivalent to its molar amount in iRGD-abraxane did
not affect tumor growth, indicating that the effect of iRGD-abrax-
ane was not due to the disruption of the integrin signaling by the516 Cancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc.iRGD peptide. An additional treatment study in a subcutaneous
22Rv1 tumor model with time-dependent tumor volume
measurements confirmed the treatment data obtained with the
orthotopic tumors (Figure S13B). A similar biodistribution of the
abraxane formulations was also observed in the subcutaneous
and orthotopic tumors (Figure S13A).
We next tested the efficacy of iRGD-abraxane in a tumor
model unrelated to 22Rv1. We chose orthotopic tumors gener-
ated with the BT474 human breast cancer cell line, which
expresses both av integrins and neuropilin-1 at the cell surfaceFigure 8. Tumor Treatment with iRGD-
Coated Nanoparticles
(A and C) Abraxane quantification in orthotopic
22Rv1 (A) and BT474 (C) xenograft models. Abrax-
ane was intravenously injected into tumor mice
3 hr earlier and captured from tumor extracts
with a taxol antibody, followed by detection with
a human albumin antibody. n = 3 for each group.
(B and D) Long-term treatment of tumor mice
with targeted abraxane conjugates. Mice bearing
orthotopic 22Rv1 (B) or BT474 (D) xenografts
were intravenously injected with peptide-coated
abraxanes every other day at 3 mg paclitaxel/kg/
injection. The treatment was continued for 14 days
in (B) and 20 days in (D). (B) shows one of three
experiments, which all gave similar results. The
total number of mice in (B) was as follows:
untargeted abraxane (ABX; n = 18), abraxane
coated with CRGDC (CRGDC-ABX; n = 10) or
iRGD (iRGD-ABX; n = 19), iRGD peptide alone as
a control (iRGD peptide; n = 10), or PBS (n = 18).
The number of mice per group was eight in (D).
Statistical analyses were performed with
Student’s t test in (A) and (C) and ANOVA in
(B) and (D). Error bars, SEM; n.s., not significant;
*p < 0.05; **p < 0.01; ***p < 0.001.
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iRGD(Figure S14). In addition, the BT474 cells are more resistant to
abraxane (paclitaxel) than 22Rv1 as shown in cytotoxicity assays
(Figure S15). When injected intravenously into the tumor mice,
the iRGD-abraxane accumulated in the tumor 11-fold more
than nontargeted abraxane and about 4-fold more than the
CRGDC-abraxane (Figure 8C). Despite the resistance of the
BT474 cells to paclitaxel, the iRGD-abraxane significantly in-
hibited the tumor growth in vivo (Figure 8D). The other abraxane
formulations or iRGD peptide alone did not show significant
effects at the same dose. Together, these results clearly demon-
strate the efficacy of iRGD in drug delivery.
DISCUSSION
Our results delineate a technology to deliver diagnostics and
therapeutics into the extravascular tumor parenchyma using a
unique tumor-specific homing peptide, iRGD. The iRGD peptide
follows a multistep tumor-targeting mechanism; the intact
peptide binds to the surface of cells expressing av integrins,
where it is proteolytically cleaved to produce the CRGDK frag-
ment. This fragment then binds to neuropilin-1 and penetrates
tumor cells and tissues (schematized in Figure 4). Several pieces
of data support the model. First, the affinity of iRGD for av integ-
rins is in the mid to low nanomolar range, similar to that of RGD
peptides previously used in tumor targeting (Koivunen et al.,
1993, 1995). Significantly, the proteolytically processed CRGDK
fragment we identified within the targeted cells has lost most of
its affinity to the integrins (about 50- to 150-fold reduction in
affinity), which is in agreement with the observation that RGDK
peptides lack cell attachment activity (Pierschbacher and Ruo-
slahti, 1984). Instead, the CRGDK fragment acquires an affinity
for neuropilin-1 that is stronger than its residual affinity for av in-
tegrins. These changes likely facilitate the transfer of CRGDK
from integrins to neuropilin-1, and the resulting penetration activ-
ities. Each step in this multistep process evidently adds to the
tumor specificity of iRGD. The expression of av integrins is
largely restricted to tumors (and other sites of angiogenesis or
tissue repair), and neuropilin-1 is elevated in multiple tumor types
(Eliceiri and Cheresh, 2001; Pellet-Many et al., 2008; Ruoslahti,
2002). The same may be true of the yet unknown processing
protease(s). For example, matriptase, a membrane-bound
protease, which preferentially cleaves proteins after a sequence
similar to the R/KXXR/K CendR motif, is overexpressed in a
number of tumor types (Uhland, 2006).
The initial recruitment of iRGD to cell surfaces appears to be
crucial for its pronounced tumor targeting ability, since the
related but non-integrin-binding peptide iRGE showed only
modest uptake into cultured cells and was inefficient in targeting
tumors in vivo. The presence of the tumor-specific recruitment
element RGD distinguishes iRGD from some previously
described tumor-targeting peptides. Jiang et al. (2004) have
described a design for tumor-homing peptides in which a
cationic cell-penetrating peptide is tethered to a negatively
charged sequence that blocks the cell-penetrating activity. The
tether contains a recognition sequence for a protease known
to be elevated in tumors. These authors achieved a 3-fold
increase in tumor homing. The greater homing we achieved
with iRGD (12-fold over a control peptide) is likely due to the
RGD-directed specific homing of the intact peptide. In addition,Cthe recruitment of iRGD to the cell surface through the RGD-
integrin interaction is probably needed for the proteolytic
cleavage that triggers the subsequent tumor penetration, as
protease inhibitors are generally inactive on cell surfaces, but
block proteolysis elsewhere (Hall et al., 1991). The unbiased
screening we performed in identifying iRGD may also have
selected for a protease that is more readily available to cleave
an incoming peptide than the proteases with known expression
but unknown availability in tumors.
Integrins shuttle between the cell surface and intracellular
compartments (Pellinen and Ivaska, 2006). Certain viral patho-
gens take advantage of this mechanism in entering cells (Pellinen
and Ivaska, 2006). However, as shown by our results, the
cell-penetrating activity of iRGD is far greater than that of
conventional RGD peptides. It far exceeds what can be accom-
plished with conventional RGD peptides and their mimics, which
only take payloads to tumor vessels (this study; Murphy et al.,
2008; Pasqualini et al., 1997). The strong tumor MRI signals
provided by iRGD-coated iron oxide nanoworms and the
enhanced tumor growth suppression by iRGD-linked abraxane
demonstrate the potential of this peptide in tumor targeting.
The molecular mechanism of the rapid tumor tissue penetra-
tion of iRGD remains to be elucidated. However, several
lines of evidence suggest that it may involve the so-called
vascular permeabilization in the tumor induced by the CendR
property of iRGD. Molecules such as vascular endothelial growth
factor-165 and some semaphorins that have exposed CendR
motifs increase vascular permeability (Jia et al., 2006; Acevedo
et al., 2008). In addition, we have recently demonstrated that a
prototypic CendR peptide, RPARPAR, induces vascular perme-
ability (Teesalu et al., 2009). Some previously described tumor-
specific cell-penetrating peptides that contain cryptic CendR
sequences may share the same CendR-dependent tissue pene-
tration mechanism (Hoffman et al., 2003; Joyce et al., 2003;
Laakkonen et al., 2002; Porkka et al., 2002). For example, LyP-
1 (CGNKRTRGC; Laakkonen et al., 2002), a cyclic peptide with
a binding site for a specific receptor (Fogal et al., 2008), contains
a cryptic CendR motif, KRTR. Like iRGD nanoparticles, LyP-1-
coated nanoparticles extravasate into tumor tissue within
minutes after an intravenous injection (Karmali et al., 2009; Laak-
konen et al., 2002; von Maltzahn et al., 2008). CendR involvement
in the activities of LyP-1 and other tumor-penetrating homing
peptides remains to be studied, but seems likely. iRGD and the
CendR system may help bring the ‘‘magic bullet’’ treatment of
cancer closer to reality.
EXPERIMENTAL PROCEDURES
Tumor Models
Animal experimentation was performed according to procedures approved by
the Animal Research Committees at the University of California, Santa Bar-
bara, San Diego, and San Francisco, and the Burnham Institute for Medical
Research. Xenografts were created by injecting nude mice with 106 human
cancer cells orthotopically, subcutaneously, or into the tibia and the brain:
prostate cancers PC-3 (Yang et al., 1999), PPC1 (Zhang et al., 2006), and
22Rv1 (Drake et al., 2005), pancreatic cancer MIA PaCa-2 (Sugahara et al.,
2008), and breast cancer BT474 (Rusnak et al., 2001). Disseminated prostate
tumors were generated by injecting 106 GFP-PC-3 cells (Yang et al., 1999) into
the left ventricle of the heart of nude mice. Tumors were monitored with the
X-ray system of the Image Station In Vivo FX (Eastman Kodak Company) or
the Illumatool Bright Light System LT-9900 (Lightools Research). Transgenicancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc. 517
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iRGDmice were maintained as described previously (Arbeit et al., 1994; Hanahan,
1985; Hezel et al., 2006).
In Vivo Peptide and Phage Homing
Approximately 200 mg of FAM-labeled synthetic peptides (Karmali et al., 2009)
were intravenously injected into tumor-bearing mice and allowed to circulate
for 15 min to 2 hr. Tissues were collected and observed under UV light (Illuma-
tool Bright Light System LT-9900) and processed for immunofluorescence
(Karmali et al., 2009) or immunohistochemistry (Sugahara et al., 2008). To
quantify the homing area of peptides within tumors, cryosections immunohis-
tochemically stained with an anti-FITC antibody were scanned with the Scan-
scope CM-1 scanner and analyzed with the ImageScope software (Aperio
Technologies; Fogal et al., 2008). To assess phage homing (Zhang et al.,
2006), 109 plaque-forming units (pfu) of T7 phage were intravenously injected
into tumor-bearing mice and allowed to circulate for 15 min. The mice were
perfused through the heart with PBS containing 1% BSA and tissues were har-
vested for immunofluorescence. In some experiments, 50 mg of function-
blocking anti-neuropilin-1 antibody (R&D Systems) or goat IgG (Abcam) was
intravenously injected into the tumor mice 15 min prior to the phage injections.
The phage were allowed to circulate for 10 min prior to perfusion and collection
of the tumors and other tissues.
Preparation of Micelles
Lipids were purchased from Avanti Polar Lipids. DSPE-PEG2,000-iRGD(FAM)
was prepared by coupling FAM-iRGD peptide bearing a cysteine on its
N terminus to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-maleimi-
de(polyethylene glycol)2,000 (DSPE-PEG2,000-maleimide) at 1:1 molar ratio at
room temperature for 4 hr. DSPE-PEG2,000-FAM was prepared by coupling
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-amino(polyethylene
glycol)2,000 (DSPE-PEG2,000-amine) with NHS-fluorescein (Pierce Biotech-
nology) at a 1:1 molar ratio for 1 hr at room temperature. DSPE-PEG2,000-Cy7
was prepared similarly using 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-amino(polyethylene glycol)2,000 and Cy7-NHS ester (GE Healthcare).
DSPE-PEG2,000-iRGD(FAM), DSPE-PEG2,000-amine, and DSPE-PEG2,000-
Cy7 in 3:6.7:0.3 molar ratios were dissolved in chloroform/methanol (3:1, v/v).
The solvent was evaporated and the dried lipid film was kept under vacuum for
8 hr and allowed to swell in PBS for 2 hr at 60C. The vial was vortexed and
sonicated to produce micelles. The micelles were sequentially filtered through
0.2 mm and 0.1 mm filters and washed with sterile PBS to remove unreacted
peptides. Control Cy7 micelles were prepared using DSPE-PEG2,000-FAM in
place of DSPE-PEG2,000-iRGD(FAM). The micelles were 15–25 nm in diameter
as measured in deionized water by dynamic laser light scattering (refractive
index, 1.59; viscosity, 0.89) on a Malvern Zetasizer Nano.
Optical In Vivo Imaging of Micelle-Peptide Conjugates
PDAC mice were injected with 100 ml of 1 mM micelles in PBS. After 3 hr, the
mice were anesthetized, shaved, and subjected to whole-body imaging with
the Odyssey Infrared Imaging System (LI-COR Biosciences).
Immunofluorescence
Tissue sections were processed as described previously (Karmali et al., 2009).
Cells were grown on collagen I-coated coverslips (BD Biosciences) overnight
and incubated with 108 pfu/ml of T7 phage for 30 min. The cells were fixed in
4% paraformaldehyde and stained with antibodies and DAPI (Molecular
Probes). The primary antibodies were rat anti-mouse CD31 monoclonal anti-
body (BD Biosciences) and rabbit anti-human av integrin (Chemicon), rabbit
anti-human neuropilin-1 (Chemicon), mouse anti-human neuropilin-1 (Miltenyi
Biotec), and rabbit anti-T7 phage (Teesalu et al., 2009) polyclonal antibodies.
The secondary antibodies, Alexa 594 goat antibodies to mouse, rat, and rabbit
IgG and Alexa 488 donkey anti-rabbit antibody, were from Molecular Probes.
Cells and tissue sections were examined by a Fluoview 500 confocal micro-
scope (Olympus America).
In Vitro Phage Binding and Penetration Assays
Suspended cells (106 cells in DMEM containing 1% BSA) were incubated with
108 pfu/ml of T7 phage for 1 hr at 4C. The cells were washed four times with
the binding buffer, lysed with lysogeny broth containing 1% NP-40, and
titrated. Phage penetration assays used the same procedure, except that518 Cancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Incthe cells were incubated with phage at 37C and that an acidic buffer (500
mM sodium chloride, 0.1 M glycine, and 1% BSA [pH 2.5]) was substituted
for the binding buffer in the second wash to remove the phage that bound to
the cell surface. Inhibitors of binding and penetration were added 20 min prior
to incubation with phage. Noninfectious phage were prepared by treating
phage with UV for 8 min in DMEM containing 1% BSA. The UV-inactivated
phage particles expressing about 200 peptides per particle were used as
multivalent inhibitors. Free synthetic peptides, mouse antibodies against
human a1, a2, avb3, avb5, a5b1, a4, or av integrins and integrin subunits
(Chemicon), and goat anti-rat neuropilin-1 (R&D Systems) with mouse and
goat IgG isotype controls (Abcam) were also tested. In some cases, 109 pfu
phage were treated with 50 mg/ml of crystalline trypsin for 5 min at 37C before
use. The proteolytic reaction was terminated with 5 mg/ml of soybean inhibitor.
Flow Cytometry
The experiments were performed as described previously (Sugahara et al.,
2003) except that 1 mM of MgSO4, CaCl2, and MnCl2 were added to the buffer
containing the integrin antibodies. The antibodies were the same as in the cell
binding assays and were detected with an Alexa 488 goat anti-mouse or goat
anti-rabbit antibody (Molecular Probes). The cells were analyzed with an Easy-
Cyte Plus System (Guava Technologies).
FAM-iRGD Fragment Isolation
PPC1 cells (107 cells in DMEM) were treated with 10 mM carbobenzoxyl-leu-
cinyl-leucinyl-leucinal (MG132; EMD Chemicals) for 30 min at 37C to inhibit
proteasomes and incubated with 20 mM of iRGD peptide labeled with FAM
at the N or C terminus. The cells were washed once with acidic buffer and lysed
in MPER (Pierce Biotechnology) containing protease inhibitors (Complete Mini
EDTA-free; Roche Applied Science) on ice for 30 min. The sample was centri-
fuged for 30 min at 12,000 rpm. The supernatant was applied onto an anti-FITC
affinity column and, after washing, bound peptides were eluted with glycine-
HCl (pH 2.8). The eluate was subjected to mass spectrometry.
Affinity Measurements
Binding affinities of iRGD and CRGDK to avb3 and avb5 integrins (US Biolog-
ical) and to neuropilin-1 (R&D Systems) were quantified by an ELISA by
measuring IC50. First, saturation binding assays were performed. Microtiter
wells coated with 5 mg/ml of the purified proteins were incubated for 1 hr at
room temperature with various concentrations of biotinylated iRGD or CRGDK
peptide in a HEPES-based buffer containing 1 mM of MgSO4 and CaCl2 for
integrin binding and PBS for neuropilin-1 binding. After washing with the
same buffer added with 0.01% Tween 20, streptavidin-conjugated horseradish
peroxidase (Vector Laboratories) was added to the wells and incubated for
30 min at room temperature. Peptide binding was quantified with 2,2-azino-
bis(3-etylbenzthiazoline-6-sulfonic acid) (Sigma-Aldrich) as a substrate. In
subsequent competition studies, microtiter wells coated with the proteins
were incubated with various concentrations of nonlabeled test peptides and
a biotinylated reporter peptide at a concentration that gave half-maximal
binding in the saturation binding assay. After 1 hr incubation at room tempera-
ture, the binding of the biotinylated peptide was quantified as above. Affinities
were determined from the inhibition data as described previously (Mu¨ller, 1980).
Magnetic Resonance Imaging
Nude mice bearing 22Rv1 orthotopic human prostate tumors were injected
intravenously with superparamagnetic iron oxide nanoworms (Park et al.,
2009) coated with iRGD or CRGDC peptides or untargeted nanoworms at
a dose of 5 mg/kg of iron. Each animal received nickel liposomes (0.2 mmol
of Ni) intravenously 1 hr prior to the nanoworms to increase the half-life of
the nanoworms (Simberg et al., 2007). The mice were repeatedly imaged
before and 3 and 7 hr after injection of the nanoworms. For each scan, the
mice were anesthetized with isoflurane and repositioned into a 30 mm diam-
eter mouse coil. The axial plains were carefully matched to previous scans
by measuring the height of the sections and comparing the vascular patterns
in the images. Iron-sensitive MRI scans consisting of T2-weighted fast spin-
echo were acquired using a 3-Tesla magnetic resonance imager (GE Health-
care). The conditions used were as follows: repetition time/echo time = 6.4
s/70 ms, echo train length = 32, readout bandwidth = ±15.6 kHz, in-plane
spatial resolution = 220 mm, field of view = (3.5 cm)2, slice thickness = 1 mm,.
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iRGDnumber of excitation = 3. After imaging, tissues of interest were harvested
without perfusion and processed for immunofluorescence.
Tumor Treatment Studies
Peptide-conjugated abraxanes were prepared and characterized as described
previously (Karmali et al., 2009). For in vitro cytotoxicity studies, 22Rv1 or
BT474cellswereseeded in96well cultureplates (53104 cellsperwell) and incu-
bated overnight. The cells were incubated with various concentrations of the
conjugates for 30 minat room temperature and washed with fresh culture media.
MTT assays (Invitrogen) to assess cell viability were performed on the cells 48 hr
later. For in vivo tumor treatment studies, nude mice bearing 2-week-old 22Rv1
orthotopic xenografts (typically about 250 mm3 in tumor volume) were intrave-
nously injected with the abraxane conjugates. The conjugates were given every
other day for 14 days at a paclitaxel equivalent of 3 mg/kg/injection. The iRGD
peptide control was administered in an equivalent amount of iRGD in each
iRGD-abraxane dose. Mice bearing subcutaneous 22Rv1 tumors were treated
similarly for 12 days, and orthotopic BT474 tumors for 20 days. The experiments
were terminated according to the guidelines by the Animal Research Committee
at the University of California, Santa Barbara. To study the homing pattern of the
abraxane conjugates in the 22Rv1 orthotopic tumors, the conjugates were intra-
venously injected to tumor-bearing mice at a dose of 3 mg/kg and allowed to
circulate for 3 hr. The mice were perfused through the heart and tissues of
interest were harvested and processed for immunofluorescence.
Abraxane Quantification
Mice bearing 22Rv1 or BT474 tumors were intravenously injected with the
abraxane conjugates at a paclitaxel equivalent of 9 mg/kg/injection. After 3 hr,
themicewere perfused through the heart and tissues of interestwere harvested.
The tissues were homogenized in cold RIPA buffer (Pierce Biotechnology) con-
taining protease inhibitors (Complete Mini EDTA-free) and kepton ice for 30 min.
The samples were then centrifuged for 30 min at 14,000 rpm. The abraxane
concentration in the supernatant was quantified with an ELISA: abraxane was
captured with a taxol antibody (Novus Biologicals) coated onto a 96 well plate
and detected with a human albumin antibody labeled with biotin (US Biological).
Statistical Analysis
Data were analyzed by two-tailed Student’s t test and one-way analysis of
variance (ANOVA), followed by suitable post-hoc test. The details are given
in Table S3.
SUPPLEMENTAL DATA
Supplemental Data include 15 figures and three tables and can be found
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S1535-6108(09)00382-1.
ACKNOWLEDGMENTS
We thank M.J. Sailor and J.-H. Park for advice on the synthesis of iron oxide
nanoworms, D.A. Cheresh for the M21 and R.M. Hoffman for the GFP-PC-3
cell lines, E. Engvall for comments on the manuscript, and L. Zhang and
T. Ja¨rvinen for advice on the phage display screens. We also thank E. Allen
and E. Drori for support with transgenic mice, J. Corbeil for help with MRI,
and R. Varghese for editing. This work was supported by National Cancer
Institute grants CA104898, CA115410, CA119414, CA119335, and CA30199
(Cancer Center Support Grant) and grants W81XWH-08-1-0727 and
W81XWH-08-BCRP-CIA from the Department of Defense.
Received: April 23, 2009
Revised: September 22, 2009
Accepted: October 7, 2009
Published: December 7, 2009
REFERENCES
Acevedo, L.M., Barillas, S., Weis, S.M., Go¨thert, J.R., and Cheresh, D.A.
(2008). Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts
as a vascular permeability factor. Blood 111, 2674–2680.CArap, W., Pasqualini, R., and Ruoslahti, E. (1998). Cancer treatment by
targeted drug delivery to tumor vasculature in a mouse model. Science 279,
377–380.
Arbeit, J.M., Mu¨nger, K., Howley, P.M., and Hanahan, D. (1994). Progressive
squamous epithelial neoplasia in K14-human papillomavirus type 16 trans-
genic mice. J. Virol. 68, 4358–4368.
Arleth, L., Ashok, B., Onyuksel, H., Thiyagarajan, P., Jacob, J., and Hjelm, R.P.
(2005). Detailed structure of hairy mixed micelles formed by phosphatidylcho-
line and PEGylated phospholipids in aqueous media. Langmuir 21, 3279–3290.
Cheresh, D.A., and Spiro, R.C. (1987). Biosynthetic and functional properties
of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attach-
ment to vitronectin, fibrinogen, and von Willebrand factor. J. Biol. Chem. 262,
17703–17711.
Curnis, F., Gasparri, A., Sacchi, A., Longhi, R., and Corti, A. (2004). Coupling
tumor necrosis factor-alpha with alphaV integrin ligands improves its antineo-
plastic activity. Cancer Res. 64, 565–571.
Drake, J.M., Gabriel, C.L., and Henry, M.D. (2005). Assessing tumor growth
and distribution in a model of prostate cancer metastasis using biolumines-
cence imaging. Clin. Exp. Metastasis 22, 674–684.
Eliceiri, B.P., and Cheresh, D.A. (2001). Adhesion events in angiogenesis. Curr.
Opin. Cell Biol. 13, 563–568.
Fogal, V., Zhang, L., Krajewski, S., and Ruoslahti, E. (2008). Mitochondrial/cell-
surface protein p32/gC1qR as a molecular target in tumor cells and tumor
stroma. Cancer Res. 68, 7210–7218.
Haley, B., and Frenkel, E. (2008). Nanoparticles for drug delivery in cancer
treatment. Urol. Oncol. 26, 57–64.
Hall, S.W., Humphries, J.E., and Gonias, S.L. (1991). Inhibition of cell surface
receptor-bound plasmin by a2-antiplasmin and a2-macroglobulin. J. Biol.
Chem. 266, 12329–12366.
Hanahan, D. (1985). Heritable formation of pancreatic beta-cell tumours in
transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.
Nature 315, 115–122.
Heldin, C.H., Rubin, K., Pietras, K., and O¨stman, A. (2004). High interstitial fluid
pressure—an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806–813.
Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A.
(2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes
Dev. 20, 1218–1249.
Hoffman, J.A., Giraudo, E., Singh, M., Zhang, L., Inoue, M., Porkka, K., Hana-
han, D., and Ruoslahti, E. (2003). Progressive vascular changes in a transgenic
mouse model of squamous cell carcinoma. Cancer Cell 4, 383–391.
Jain, R.K. (1990). Vascular and interstitial barriers to delivery of therapeutic
agents in tumors. Cancer Metastasis Rev. 9, 253–266.
Jia, H., Bagherzadeh, A., Hartzoulakis, B., Jarvis, A., Lo¨hr, M., Shaikh, S., Aqil,
R., Cheng, L., Tickner, M., Esposito, D., et al. (2006). Characterization of a bicy-
clic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of
vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1
in KDR signaling. J. Biol. Chem. 281, 13493–13502.
Jiang, T., Olson, E.S., Nguyen, Q.T., Roy, M., Jennings, P.A., and Tsien, R.Y.
(2004). Tumor imaging by means of proteolytic activation of cell-penetrating
peptides. Proc. Natl. Acad. Sci. USA 101, 17867–17872.
Joyce, J.A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., and Ha-
nahan, D. (2003). Stage-specific vascular markers revealed by phage display
in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4, 393–403.
Karmali, P.P., Kotamraju, V.R., Kastantin, M., Black, M., Missirlis, D., Tirrell, M.,
and Ruoslahti, E. (2009). Targeting of albumin-embedded paclitaxel nanopar-
ticles to tumors. Nanomedicine 5, 73–82.
Koivunen, E., Gay, D.A., and Ruoslahti, E. (1993). Selection of peptides binding
to the alpha 5 beta 1 integrin from phage display library. J. Biol. Chem. 268,
20205–20210.
Koivunen, E., Wang, B., and Ruoslahti, E. (1995). Phage libraries display-
ing cyclic peptides with different ring sizes: ligand specificities of the RGD-
directed integrins. Biotechnology (NY) 13, 265–270.ancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier Inc. 519
Cancer Cell
iRGDLaakkonen, P., Porkka, K., Hoffman, J.A., and Ruoslahti, E. (2002). A tumor-
homing peptide with a targeting specificity related to lymphatic vessels. Nat.
Med. 8, 751–755.
Lambert, S., Bouttier, M., Vassy, R., Seigneuret, M., Petrow-Sadowski, C.,
Janvier, S., Heveker, N., Ruscetti, F.W., Perret, G., Jones, K.S., and Pique,
C. (2009). HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry
of VEGF165. Blood 113, 5176–5185.
McAteer, M.A., Sibson, N.R., von Zur Muhlen, C., Schneider, J.E., Lowe, A.S.,
Warrick, N., Channon, K.M., Anthony, D.C., and Choudhury, R.P. (2007). In
vivo magnetic resonance imaging of acute brain inflammation using micropar-
ticles of iron oxide. Nat. Med. 13, 1253–1258.
Mu¨ller, R. (1980). Calculation of average antibody affinity in anti-hapten sera
from data obtained by competitive radioimmunoassay. J. Immunol. Methods
34, 345–352.
Murphy, E.A., Majeti, B.K., Barnes, L.A., Makale, M., Weis, S.M., Lutu-Fuga,
K., Wrasidlo, W., and Cheresh, D.A. (2008). Nanoparticle-mediated drug
delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci.
USA 105, 9343–9348.
Park, J.H., von Maltzahn, G., Zhang, L., Derfus, A.M., Simberg, D., Harris, T.J.,
Ruoslahti, E., Bhatia, S.N., and Sailor, M.J. (2009). Systematic surface engi-
neering of magnetic nanoworms for in vivo tumor targeting. Small 5, 694–700.
Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997). Alpha v integrins as
receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15,
542–546.
Pellet-Many, C., Frankel, P., Jia, H., and Zachary, I. (2008). Neuropilins: struc-
ture, function and role in disease. Biochem. J. 411, 211–226.
Pellinen, T., and Ivaska, J. (2006). Integrin traffic. J. Cell Sci. 119, 3723–3731.
Pierschbacher, M.D., and Ruoslahti, E. (1984). Cell attachment activity of fibro-
nectin can be duplicated by small synthetic fragments of the molecule. Nature
309, 30–33.
Porkka, K., Laakkonen, P., Hoffman, J.A., Bernasconi, M., and Ruoslahti, E.
(2002). A fragment of the HMGN2 protein homes to the nuclei of tumor cells
and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA 99, 7444–7449.
Ruoslahti, E. (2002). Specialization of tumour vasculature. Nat. Rev. Cancer 2,
83–90.
Ruoslahti, E. (2003). The RGD story: a personal account. Matrix Biol. 22,
459–465.
Ruoslahti, E., and Rajotte, D. (2000). An address system in the vasculature of
normal tissues and tumors. Annu. Rev. Immunol. 18, 813–827.
Rusnak, D.W., Lackey, K., Affleck, K., Wood, E.R., Alligood, K.J., Rhodes, N.,
Keith, B.R., Murray, D.M., Knight, W.B., Mullin, R.J., and Gilmer, T.M. (2001).520 Cancer Cell 16, 510–520, December 8, 2009 ª2009 Elsevier IncThe effects of the novel, reversible epidermal growth factor receptor/ErbB-2
tyrosine kinase inhibitor, GW2016, on the growth of human normal and
tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85–94.
Simberg, D., Duza, T., Park, J.H., Essler, M., Pilch, J., Zhang, L., Derfus, A.M.,
Yang, M., Hoffman, R.M., Bhatia, S., et al. (2007). Biomimetic amplification of
nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA 104, 932–936.
Sipkins, D.A., Cheresh, D.A., Kazemi, M.R., Nevin, L.M., Bednarski, M.D., and
Li, K.C. (1998). Detection of tumor angiogenesis in vivo by alphaVbeta3-tar-
geted magnetic resonance imaging. Nat. Med. 4, 623–626.
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., and Klagsbrun, M. (1998).
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-
specific receptor for vascular endothelial growth factor. Cell 92, 735–745.
Sokoloff, A.V., Bock, I., Zhang, G., Sebestye´n, M.G., and Wolff, J.A. (2000).
The interactions of peptides with the innate immune system studied with use
of T7 phage peptide display. Mol. Ther. 2, 131–139.
Steinhauer, D.A. (1999). Role of hemagglutinin cleavage for the pathogenicity
of influenza virus. Virology 258, 1–20.
Sugahara, K.N., Murai, T., Nishinakamura, H., Kawashima, H., Saya, H., and
Miyasaka, M. (2003). Hyaluronan oligosaccharides induce CD44 cleavage
and promote cell migration in CD44-expressing tumor cells. J. Biol. Chem.
278, 32259–32265.
Sugahara, K.N., Hirata, T., Tanaka, T., Ogino, S., Takeda, M., Terasawa, H.,
Shimada, I., Tamura, J., ten Dam, G.B., van Kuppevelt, T.H., and Miyasaka,
M. (2008). Chondroitin sulfate E fragments enhance CD44 cleavage and
CD44-dependent motility in tumor cells. Cancer Res. 68, 7191–7199.
Teesalu, T., Sugahara, K.N., Kotamraju, V.R., and Ruoslahti, E. (2009). C-end
rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue pene-
tration. Proc. Natl. Acad. Sci. USA 106, 16157–16162.
Uhland, K. (2006). Matriptase and its putative role in cancer. Cell. Mol. Life Sci.
63, 2968–2978.
von Maltzahn, G., Ren, Y., Park, J.H., Min, D.H., Kotamraju, V.R., Jayakumar,
J., Fogal, V., Sailor, M.J., Ruoslahti, E., and Bhatia, S.N. (2008). In vivo tumor
cell targeting with ‘‘click’’ nanoparticles. Bioconjug. Chem. 19, 1570–1578.
Wickham, T.J. (2000). Targeting adenovirus. Gene Ther. 7, 110–114.
Yang, M., Jiang, P., Sun, F.X., Hasegawa, S., Baranov, E., Chishima, T., Shi-
mada, H., Moossa, A.R., and Hoffman, R.M. (1999). A fluorescent orthotopic
bone metastasis model of human prostate cancer. Cancer Res. 59, 781–786.
Zhang, L., Giraudo, E., Hoffman, J.A., Hanahan, D., and Ruoslahti, E. (2006).
Lymphatic zip codes in premalignant lesions and tumors. Cancer Res. 66,
5696–5706..
